CClinicalTrials.gg
Not yet recruitingNCT06960499Updated May 7, 2025

Predictors of Physical Activity in Adult Patients With Hemophilic Arthropathy

An observational study in Hemophilia, sponsored by Universidad Católica San Antonio de Murcia. Not yet recruiting at 1 site in Spain. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Universidad Católica San Antonio de Murcia · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
88
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

Introduction. The development of hemophilic arthropathy causes degenerative joint damage that leads to functional impairment, limiting physical activity and causing disability in patients with hemophilia.

Objectives. i) To assess the level of physical activity in patients with hemophilia; ii) To identify the best predictive model for physical activity in adult patients with hemophilic arthropathy.

Material and method. Multicenter cross-sectional cohort study. Eighty-eight patients will be recruited. The dependent variable will be physical activity (International Physical Activity Questionnaire). Secondary variables will be kinesiophobia (Tampa Kinesiophobia Scale), functionality (Functional Independence Scale in Hemophilia), pain intensity, and clinical, anthropometric, and sociodemographic variables.

02

Conditions studied

  • Hemophilia

Keywords

  • Hemophilia
  • Physical activity
  • Kinesiophobia
  • Functionality
  • Joint pain
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with hemophilia A or B and hemophilic arthropathy where it is desired to assess the degree of physical activity and the main predictive factors for this.

Inclusion criteria

  • Patients with hemophilia A or B
  • Over the age of majority
  • With a medical diagnosis of severe phenotype of the disease
  • With a medical diagnosis of hemophilic arthropathy in the lower limbs
  • Under on-demand or prophylactic drug treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients who require technical aids for walking
  • Patients who are dependent for activities of daily living
  • Patients over the age of 60
  • Patients with cognitive impairments that prevent them from understanding the questionnaires
04

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
88 participants (estimated)
Patient registry
No

Groups and cohorts

  • Observacional group

    Patients with hemophilia A or B, of legal age, with a medical diagnosis of severe phenotype of the disease and hemophilic arthropathy in the lower limbs.

    Other: Surveys

Interventions

  • OtherSurveys

    No intervention will be carried out in this study; the recruited patients will only complete the questionnaires provided below

05

What researchers measure

Primary outcomes

  1. Measurement of physical activity level

    Physical activity levels will be assessed using the International Physical Activity Questionnaire (IPAQ). This tool assesses physical activity levels in adults aged 18 to 65. It consists of seven questions that ask about the frequency, duration, and intensity of physical activity performed in the last week. It also assesses the time spent walking and sitting. The results are classified into three categories: low, moderate, and high activity. The unit of measurement is metabolic equivalent task (METS), where a higher number of METS indicates greater physical activity.

    Time frame: Screening visit

Secondary outcomes

  1. Measurement of fear of movement

    Fear of movement will be measured using the Tampa Kinesiophobia Scale (TSK). This self-reported questionnaire consists of 17 items, using a 4-point Likert scale. It comprises two subscales: avoidance of physical exertion due to fear of injury or pain, and belief that significant underlying medical problems exist. The total score ranges from 17 to 68 points, with a score of 37 or more indicating a high level of kinesiophobia

    Time frame: Screening visit

  2. Measurement of degree of functional independence

    The degree of functional independence of patients will be measured using the Functional Independence Scale for Hemophilia (FISH). This tool measures eight activities of daily living: eating, personal hygiene, dressing, transferring from a chair, squatting, walking, climbing stairs, and running. Each activity is rated according to the level of assistance required, using a scale from 1 to 4. The total score can reach a maximum of 32 points, with a higher score indicating greater functional independence.

    Time frame: Screening visit

  3. Measurement of the joint pain

    Pain intensity will be measured using the Visual Analog Scale (VAS). This is a simple and effective tool for measuring pain intensity. It consists of a horizontal line, usually 10 cm long, with one end representing "no pain" and the other "maximum pain imaginable."

    Time frame: Screening visit

  4. Measurement of age

    The sociodemographic variable age will be measured in months completed from the date of birth

    Time frame: Screening visit

  5. Measurement of marital status

    The sociodemographic variable marital status will be measured as a qualitative variable (single/married/divorced/widowed).

    Time frame: Screening visit

  6. Measurement of educational level

    The sociodemographic variable educational level will be measured as a qualitative variable (primary education/secondary education/university education/vocational training).

    Time frame: Screening visit

  7. Measurement of employment status

    The sociodemographic variable employment status will be measured as a qualitative variable (self-employed/employed by others/civil servant/unemployed/unable to work/retired).

    Time frame: Screening visit

  8. Measurement of hemophilia type

    The clinical variable hemophilia type will be measured as a dichotomous variable (hemophilia A/hemophilia B).

    Time frame: Screening visit

  9. Measurement of type of drug treatment

    The clinical variable drug treatment will be measured as a dichotomous variable (on-demand treatment/prophylactic treatment).

    Time frame: Screening visit

  10. Measurement of inhibitor development

    The clinical variable development of antibodies prior to FVIII/FIX concentrates (inhibitors) will be measured as a dichotomous variable (yes/no).

    Time frame: Screening visit

  11. Measurement of weight

    The anthropometric variable weight will be measured as a quantitative variable (measured in kg).

    Time frame: Screening visit

  12. Measurement of height

    The anthropometric variable height will be measured as a quantitative variable (measured in cm).

    Time frame: Screening visit

06

Study locations

1 site
  • Universidad Católica San Antonio de Murcia
    Murcia, 33006, Spain
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06960499
Lead sponsor
Universidad Católica San Antonio de Murcia
Responsible party
Rubén Cuesta-Barriuso, PhD (Principal Investigator, Universidad Católica San Antonio de Murcia) — Principal investigator
First posted
May 7, 2025
Start date
May 4, 2025 (estimated)
Primary completion
May 28, 2025 (estimated)
Completion
Jun 20, 2025 (estimated)
Last update
May 7, 2025

Study contacts

Rubén Cuesta-Barriuso, PhD
Contact
cuestaruben@uniovi.es
607547274
Rubén Cuesta-Barriuso
principal investigator · Universidad de Oviedo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion